Strata Critical Medical, Inc. reported significant financial developments in its latest 10-Q filing for the third quarter of 2025, showcasing a revenue increase of 36.7% year-over-year, reaching $49.3 million compared to $36.1 million in the same period of 2024. For the nine months ending September 30, 2025, total revenue was $130.4 million, an 18% increase from $110.4 million in the prior year. The company attributed this growth to increased flight hours, enhanced ground transportation services, and contributions from its recent acquisition of Keystone Perfusion Services, which added approximately $2.8 million to revenue.
Despite the revenue growth, Strata reported a net loss from continuing operations of $9.7 million for the third quarter, compared to a loss of $5.6 million in the same quarter of 2024. The nine-month net loss from continuing operations also widened to $14.7 million from $8.7 million year-over-year. The increase in losses was primarily driven by higher operating expenses, which rose to $54.9 million in the third quarter, up from $43.2 million in the previous year, largely due to legal expenses, transaction costs related to the Keystone acquisition, and increased staffing costs.
Strategically, Strata completed the sale of its Passenger business to Joby Aero, Inc. on August 29, 2025, for approximately $76 million, which has been classified as a discontinued operation. This divestiture allows the company to focus on its core medical logistics services. Following this, Strata acquired Keystone Perfusion Services on September 16, 2025, for a total consideration of $110 million, which included cash and stock. This acquisition is expected to enhance Strata's service offerings in the organ recovery and perfusion sectors.
Operationally, Strata's total assets increased to $335.1 million as of September 30, 2025, up from $256.7 million at the end of 2024, driven by the acquisition of Keystone and the cash received from the sale of the Passenger business. The company reported a total of 86,050,917 shares of common stock outstanding as of November 3, 2025. The company’s cash and cash equivalents also improved, totaling $22.8 million, alongside short-term investments of $53.2 million.
Looking ahead, Strata anticipates that the integration of Keystone will provide operational synergies and enhance its market position in the transplant logistics sector. The company expects to leverage its increased liquidity and operational capabilities to meet its strategic goals, although it acknowledges the inherent risks associated with market conditions and the integration of new acquisitions.
About Blade Air Mobility, Inc.
Blade Air Mobility, Inc. provides air transportation and logistics services, specializing in passenger flights and medical organ transport primarily in the U.S. Northeast and Southern Europe. Its asset-light model leverages third-party aircraft operators, supported by proprietary technology for real-time flight and logistics management. Blade offers helicopter, seaplane, and fixed-wing services, focusing on cost-effective, reliable urban air mobility and organ transport solutions for hospitals, transplant centers, and individual customers.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.